Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Enterprise Value: 2016-2025

Historic Enterprise Value for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Sep 2025 value amounting to $5.9 billion.

  • Rhythm Pharmaceuticals' Enterprise Value rose 104.13% to $5.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year increase of 120.14%. This contributed to the annual value of $3.1 billion for FY2024, which is 27.82% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Enterprise Value is $5.9 billion, which was up 65.87% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Enterprise Value registered a high of $5.9 billion during Q3 2025, and its lowest value of -$26.8 million during Q2 2022.
  • Its 3-year average for Enterprise Value is $2.5 billion, with a median of $2.4 billion in 2023.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Enterprise Value crashed by 104.36% in 2022, and later spiked by 2,651.73% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Enterprise Value (Quarterly) stood at $206.5 million in 2021, then skyrocketed by 533.07% to $1.3 billion in 2022, then skyrocketed by 86.69% to $2.4 billion in 2023, then rose by 27.82% to $3.1 billion in 2024, then soared by 104.13% to $5.9 billion in 2025.
  • Its Enterprise Value was $5.9 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $2.8 billion in Q1 2025.